Faculty

Back to Index
Daniel Pelletier, MD
Professor of Neurology
Eric and Peggy Lieber Chair in Neurology
Vice Chair, Clinical Research, Department of Neurology
Division Chief, Neuro Immunology and USC Multiple Sclerosis Center
Neurology
CHP 206 1540 Alcazar St. Health Sciences Campus Los Angeles

Overview

Dr. Pelletier is a clinician-scientist born and educated in the Province of Quebec, Canada. After first receiving a bachelor degree in Computer Sciences and studying Artificial Intelligence at the University of Connecticut, Dr. Pelletier received his M.D. degree in 1994 and completed his Neurology training at Laval University and at McGill University. He subsequently received research training in multiple sclerosis and advanced magnetic resonance imaging techniques at the Montreal Neurological Institute.

He joined the University of California, San Francisco in 1999 as a recipient of a National Multiple Sclerosis Physician Fellowship Award Grant for his work in molecular imaging. He then received the Harry Weaver Neuroscientist Scholar Award in 2005 from the National Multiple Sclerosis Society for his research on magnetic resonance spectroscopy at high field strength and was a recipient of a Distinguished Professorship endowed chair in Neurology at UCSF in 2009. Dr. Pelletier joined Yale University in January 2011 to lead the MS Program as Chief of the Neuro-Immunology Division until March 2015. He recently accepted an appointment at the University of Southern California in Los Angeles to become Vice-Chair of Research and Chief of the Neuro-Immunology and MS Division.

Dr. Pelletier has received extra-mural research funding from the U.S. National Multiple Sclerosis Society, National Institute of Health, and the Immune Tolerance Network. His work has been published in New England Journal of Medicine, Brain, Annals of Neurology, Lancet Neurology, British Medical Journal, Proceedings of the National Academy of Sciences, Neuroimage, Magnetic Resonance in Medicine, Human Brain Mapping, Neurology, and Human Molecular Genetics.

Publications

Radiologically isolated syndrome in children: Clinical and radiologic outcomes. Neurol Neuroimmunol Neuroinflamm. 2017 Nov; 4(6):e395. View in: PubMed

Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. J Magn Reson Imaging. 2017 Oct; 46(4):951-971. View in: PubMed

. View in: PubMed

Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1 -weighted brain MRI acquisitions. Magn Reson Med. 2017 Jun 15. View in: PubMed

Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017 Feb 28; 88(9):826-831. View in: PubMed

Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. J Magn Reson Imaging. 2017 Jan; 45(1):187-198. View in: PubMed

Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510. View in: PubMed

Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. J Neurol Sci. 2016 Sep 15; 368:334-6. View in: PubMed

Multiple sclerosis: Rapid diagnosis or right diagnosis? Neurology. Multiple sclerosis: Rapid diagnosis or right diagnosis? Neurology. 2016 Aug 16; 87(7):652-3. View in: PubMed

Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis. J Neurol Sci. 2016 Jul 15; 366:229-233. View in: PubMed

Power estimation for non-standardized multisite studies. Neuroimage. 2016 Jul 01; 134:281-294. View in: PubMed

Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? Curr Opin Neurol. Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? Curr Opin Neurol. 2016 Jun; 29(3):237-42. View in: PubMed

Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016 Mar; 6:10-20. View in: PubMed

Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. Ann Neurol. 2016 Feb; 79(2):288-94. View in: PubMed

Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol. 2016 Feb; 23(2):327-32. View in: PubMed

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016 12; 12(12):714-722. View in: PubMed

Longitudinal associations between brain structural changes and fatigue in early MS. Mult Scler Relat Disord. 2016 Jan; 5:29-33. View in: PubMed

Longitudinal associations between MRI and cognitive changes in very early MS. Mult Scler Relat Disord. 2016 Jan; 5:47-52. View in: PubMed

Retinal axonal loss in very early stages of multiple sclerosis. Eur J Neurol. 2015 Jul; 22(7):1138-41. View in: PubMed

(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015 Jun; 42(7):1081-92. View in: PubMed

Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e102. View in: PubMed

Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015 Mar-Apr; 17(2):74-82. View in: PubMed

Genetic associations with brain cortical thickness in multiple sclerosis. Genes Brain Behav. 2015 Feb; 14(2):217-27. View in: PubMed

The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials. 2014 Nov; 39(2):288-93. View in: PubMed

Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord. 2014 Nov; 3(6):720-7. View in: PubMed

Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014 Aug; 13(8):807-22. View in: PubMed

In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol. 2014 Aug; 76(2):269-78. View in: PubMed

Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol. 2014 Jul 01; 71(7):840-7. View in: PubMed

Metric optimization for surface analysis in the Laplace-Beltrami embedding space. IEEE Trans Med Imaging. 2014 Jul; 33(7):1447-63. View in: PubMed

A randomized controlled phase II trial of riluzole in early multiple sclerosis. Ann Clin Transl Neurol. 2014 May; 1(5):340-7. View in: PubMed

Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014; 9(3):e90509. View in: PubMed

Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol Med. Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol Med. 2014 Jan; 44(2):349-59. View in: PubMed

Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp. 2014 Jan; 35(1):30-7. View in: PubMed

Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol. 2013 Nov 13; 13:173. View in: PubMed

Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet. 2013 Oct 15; 22(20):4194-205. View in: PubMed

The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET study. Brain Behav Immun. 2013 Oct; 33:131-8. View in: PubMed

A genome-wide association study of brain lesion distribution in multiple sclerosis. Brain. 2013 Apr; 136(Pt 4):1012-24. View in: PubMed

The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology. 2013 Jan 08; 80(2):210-9. View in: PubMed

A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler. 2013 Jan; 19(1):69-75. View in: PubMed

Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013 Jan; 75(1):76-82. View in: PubMed

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov; 72(5):779-87. View in: PubMed

Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler. 2012 Sep; 18(9):1297-302. View in: PubMed

Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012 Aug; 72(2):234-40. View in: PubMed

A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012 Jul 31; 79(5):412-9. View in: PubMed

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10; 78(15):1171-8. View in: PubMed

Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 Apr; 11(4):349-60. View in: PubMed

Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert Rev Neurother. 2012 Mar; 12(3):323-33. View in: PubMed

Fingolimod for multiple sclerosis. N Engl J Med. 2012 Jan 26; 366(4):339-47. View in: PubMed

Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011 Dec; 68(12):1514-20. View in: PubMed

Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011 Sep; 17(9):1098-106. View in: PubMed

Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective. AJNR Am J Neuroradiol. 2011 Mar; 32(3):424-7. View in: PubMed

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92. View in: PubMed

Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011 Feb 03; 6(2):e16664. View in: PubMed

Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med. 2011 Jan 18; 3(1):3. View in: PubMed

Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011; 6(2):e16664. View in: PubMed

Conformal metric optimization on surface (CMOS) for deformation and mapping in Laplace-Beltrami embedding space. Med Image Comput Comput Assist Interv. 2011; 14(Pt 2):327-34. View in: PubMed

Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain. 2010 Sep; 133(9):2603-11. View in: PubMed

High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patients. J Neuroimaging. 2010 Apr; 20(2):141-7. View in: PubMed

MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging. 2010 Feb; 28(2):163-70. View in: PubMed

Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009 Aug; 66(8):967-71. View in: PubMed

Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci. 2009 Jul 15; 282(1-2):61-6. View in: PubMed

Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet. 2009 Jun 01; 18(11):2078-90. View in: PubMed

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009 May 19; 72(20):1760-5. View in: PubMed

Nonrigid registration of multiple sclerosis brain images using lesion inpainting for morphometry or lesion mapping. Hum Brain Mapp. 2009 Apr; 30(4):1060-7. View in: PubMed

Sorting through the pediatric MS spectrum with brain MRI. Nat Rev Neurol. 2009 Apr; 5(4):186-8. View in: PubMed

Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009 Mar 03; 72(9):800-5. View in: PubMed

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 Feb 15; 18(4):767-78. View in: PubMed

Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 Jan; 132(Pt 1):250-9. View in: PubMed

Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol. 2008 Dec; 64(6):707-13. View in: PubMed

Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry. 2008 Nov; 79(11):1236-44. View in: PubMed

Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A. 2008 Aug 19; 105(33):11839-44. View in: PubMed

MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008 Jul; 7(7):615-25. View in: PubMed

Development of a robust method for generating 7. 0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. Neuroimage. 2008 Feb 15; 39(4):1682-92. View in: PubMed

Whole brain voxel-wise analysis of single-subject serial DTI by permutation testing. Neuroimage. 2008 Feb 15; 39(4):1693-705. View in: PubMed

Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data. MAGMA. 2007 Jun; 20(3):143-55. View in: PubMed

Multislice brain myelin water fractions at 3T in multiple sclerosis. J Neuroimaging. 2007 Apr; 17(2):156-63. View in: PubMed

TE-averaged two-dimensional proton spectroscopic imaging of glutamate at 3 T. Neuroimage. 2006 May 01; 30(4):1171-8. View in: PubMed

A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006 Jan; 20(1):27-36. View in: PubMed

Measurement of in vivo multi-component T2 relaxation times for brain tissue using multi-slice T2 prep at 1. 5 and 3 T. Magn Reson Imaging. 2006 Jan; 24(1):33-43. View in: PubMed

Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol. 2005 Nov; 58(5):812-3. View in: PubMed

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4):375-81. View in: PubMed

Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005 May; 128(Pt 5):1016-25. View in: PubMed

The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients. Mult Scler. 2004 Dec; 10(6):626-9. View in: PubMed

Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging. J Neurol Neurosurg Psychiatry. 2004 Sep; 75(9):1281-6. View in: PubMed

Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimaging. 2004 Jul; 14(3 Suppl):11S-19S. View in: PubMed

Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. Arch Neurol. 2004 Jul; 61(7):1081-6. View in: PubMed

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler. 2004 Jun; 10 Suppl 1:S58-61. View in: PubMed

Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ. 2004 Mar 27; 328(7442):731. View in: PubMed

Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med. 2004 Mar; 51(3):435-40. View in: PubMed

Directional diffusion in relapsing-remitting multiple sclerosis: a possible in vivo signature of Wallerian degeneration. J Magn Reson Imaging. 2003 Oct; 18(4):420-6. View in: PubMed

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry. 2003 Jul; 74(7):950-2. View in: PubMed

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003 Mar; 72(3):710-6. View in: PubMed

Standardized, reproducible, high resolution global measurements of T1 relaxation metrics in cases of multiple sclerosis. AJNR Am J Neuroradiol. 2003 Jan; 24(1):58-67. View in: PubMed

T2 relaxation time histograms in multiple sclerosis. Magn Reson Imaging. 2002 Dec; 20(10):733-41. View in: PubMed

Dissociating perceptual and conceptual implicit memory in multiple sclerosis patients. Brain Cogn. 2002 Oct; 50(1):51-61. View in: PubMed

3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain. Magn Reson Imaging. 2002 Oct; 20(8):599-606. View in: PubMed

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol. 2001 Nov; 248(11):979-86. View in: PubMed

Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000 Jun; 215(3):824-30. View in: PubMed

Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol. 2000 Feb; 47(2):234-7. View in: PubMed

Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol. 1999 Feb; 45(2):247-50. View in: PubMed

Powered bySC CTSI